Literature DB >> 1380053

[Sequential changes of HPV DNA, the expression of EGF-R and CD-14, and histopathological findings in HPV infected benign epithelium and dysplastic lesions of the uterine cervix].

M Suzuki1, Y Furugen, R Miyazaki, T Yamamoto, M Takada.   

Abstract

In regard to cases in which HPV DNA was detected in the uterine cervix by the Southern blot method, we studied both changes in HPV DNA and histological diagnosis, and moreover we studied the relationship between CD-14 (monocyte/macrophage), EGF-R, and HPV DNA. 1) Changes in HPV DNA, regardless of the HPV type in benign lesions of the uterine cervix, almost all became negative within 1 year. 2) In 1 year benign lesions, the manifestation frequency of CD-14 was higher from the initial examination and during the subsequent 3 months when HPV DNA was detected. 3) HPV DNA in cases of mild dysplasia was detected after 1 year in 41% (7/17), but it continued for 3 years only in 3 cases. 4) Cases of moderate to severe dysplasia, which are though to have developed cancer at an early period of within 1-1.5 years included 26.7% (4/15), and HPV DNA was continually detected in them. The characteristics of these cases were: (1) The HPV 16 type was the main type. (2) The mean age was 34.8 years, which was younger than in regressed cases with a mean age of 43.1 years. (3) The dysplasia occupation rate in the uterine cervix was higher. 5) In 7 cases of moderate to severe dysplasia which regressed from squamous metaplasia, HPV DNA was detected at 1 year in 71.4% (5/7), but at 2-3 years it became undetectable in all cases, so that it has a close relationship with this histological regression.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380053

Source DB:  PubMed          Journal:  Nihon Sanka Fujinka Gakkai Zasshi        ISSN: 0300-9165


  1 in total

1.  Establishment of the cell line, HeLa-CD14, transfected with the human CD14 gene.

Authors:  Bo-Tao Ning; Yong-Min Tang
Journal:  Oncol Lett       Date:  2012-01-09       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.